En Carta Diagnostics
Develops at-home molecular diagnostic tests for Lyme disease and sexually transmitted infections, aiming to bring lab-style testing into consumer settings.
Overview
En Carta Diagnostics is developing at-home molecular tests focused on Lyme disease and sexually transmitted infections. Its products target consumer and healthcare markets seeking more accessible diagnostic options outside traditional clinical testing sites. The company’s key positioning is the move of molecular diagnostics into an at-home format for conditions where timely testing can be important. In July 2026, it raised €5 million in an undisclosed round to bring these tests to market, representing its disclosed total funding to date.
Funding History
En Carta Diagnostics raises €5 million to bring at-home molecular tests for Lyme disease and STIs to market
Frequently Asked Questions
- How much funding does AI Funding track for En Carta Diagnostics?
- AI Funding tracks €5M for En Carta Diagnostics across 1 funding round in this database.
- Who are En Carta Diagnostics's investors?
- En Carta Diagnostics's investors include Blue Forest Ventures.
- What does En Carta Diagnostics do?
- En Carta Diagnostics is developing at-home molecular tests focused on Lyme disease and sexually transmitted infections. Its products target consumer and healthcare markets seeking more accessible diagnostic options outside traditional clinical testing sites. The company’s key positioning is the move of molecular diagnostics into an at-home format for conditions where timely testing can be important. In July 2026, it raised €5 million in an undisclosed round to bring these tests to market, representing its disclosed total funding to date.
- Where is En Carta Diagnostics headquartered?
- En Carta Diagnostics is headquartered in San Francisco, CA.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.